Browse more cannabis research, findings, methods, and limitations.
Mendelian randomization study found no causal link between cannabis use disorder and any cancer type, while opioid use disorder showed potential associations with bladder cancer and leukemia.
Study of 490 males found cannabis use disorder associated with altered DAT1 dopamine gene methylation, which correlated with higher neuroticism and anxiety, suggesting epigenetic pathways for cannabis's psychological effects.
Lab study found CBD selectively blocked pro-inflammatory macrophage activation by disrupting metabolic reprogramming and PI3K/Akt signaling, without affecting TNF-alpha production.
Study identified distinct subgroups of cannabis users based on how they assess impairment risk, monitor their use, and plan safe transportation, revealing heterogeneity that one-size-fits-all policies miss.
National analysis of 552,160 asthma hospitalizations found cannabis use disorder associated with 2.4x higher mortality, 35% more severe exacerbations, and higher hospital charges.
Lab analysis found 67% of CBD tinctures sold online had inaccurate labels, with broad-spectrum products significantly less accurate than full-spectrum. Two products contained undisclosed THC.
National survey data showed adolescents with depression or bipolar disorder who use cannabis had significantly higher rates of suicidal ideation and attempts compared to non-users with the same diagnoses.
Lab study found a 1:1 CBD:THC combination most effectively suppressed viral immune receptor (TLR7/8) inflammatory signaling in human immune cells, outperforming either cannabinoid alone.
National treatment data showed cannabis-related admissions fell overall from 2010-2021, but recreational legalization was associated with a delayed increase in treatment-seeking starting four years after implementation.
Systematic review of 22 medicinal plants for chemotherapy-induced nausea found cannabis, ginger, and turmeric had the strongest evidence for multi-targeted antiemetic and chemosensitizing effects.
Multi-species study found daily THC causes inflammatory gliosis specifically in the adolescent amygdala through astrocyte CB1 receptors. CBD co-treatment prevented the inflammation but not all neural changes.
Mouse study showed CBD and CBG each reduced colitis-related gut pain, and a four-cannabinoid combination achieved the same effect at individually subtherapeutic doses through sodium and calcium channel mechanisms.
Analysis of 806 million US emergency visits found cannabinoid hyperemesis syndrome visits surged 7.5-fold from 2016-2020, with young adults 18-25 at 3.6x higher risk.
Postmortem testing of children under 10 showed THC positivity rising significantly from 2018-2024, with the vast majority of cases in children age 2 or younger, including 31% in newborns.
Comprehensive review cataloged CBD interactions across endocannabinoid receptors, ion channels, CYP450 enzymes, inflammatory pathways, and sex hormones, spanning effects on multiple body systems.
A 6-month observational study of 58 patients found cariprazine significantly improved both schizophrenia symptoms and cannabis dependence, with large improvements across all outcome measures.
Rat study found the antioxidant N-acetylcysteine prevented cognitive, synaptic, and neurochemical damage from adolescent THC exposure, pointing to oxidative stress as a key mechanism of harm.
UK Biobank study of 67,713 older adults found lifetime cannabis users performed better across five cognitive domains, though longer use duration was linked to faster processing speed decline.
Study of 10 neurological conditions found cannabis abuse consistently linked to higher ER visits and more pain, though mortality differences were not statistically significant.
Study of 223,068 Australian births found children exposed to maternal cannabis use disorder had 79% higher anxiety risk and 2.5x higher PTSD risk.
Australian population study found children of mothers with cannabis use disorder during pregnancy had 3.5x higher risk of disruptive behavioral disorders across all exposure windows.
Lab study found a cannabinoid product killed papillary thyroid cancer cells by activating the tumor suppressor p53 and suppressing cancer-promoting genes BCL-2 and c-Myc.
Genomic analysis of 30,000+ individuals found genetic variants influence endocannabinoid system gene expression in tissue-specific patterns, explaining why cannabinoid responses vary between individuals.
Review found the endocannabinoid system is a promising treatment target for child and adolescent psychiatric disorders, but compounds targeting it without cannabis's side effects need further development.
Rat Parkinson's study found blocking CB2 receptors improved sleep while activating them improved memory, revealing paradoxical endocannabinoid roles in non-motor symptoms.
Clinical trial of 12 volunteers found novel sublingual, rectal, and vaporizer cannabis products had faster cannabinoid absorption than approved products like Sativex, with comparable safety.
Systematic review found only 11 total studies on technology-based interventions for cannabis use in psychosis, despite the rapid growth of digital mental health tools.
Daily diary study found college students with ADHD used cannabis more frequently, driven specifically by stronger motivation to cope with negative emotions.
Survey of 350 Australian cancer patients found 19% used medical cannabis, mostly for pain. Only 28% of users believed the evidence was high quality, and most got information from non-clinical sources.
Colorado surveillance data showed 13.3% of birthing individuals used cannabis perinatally, with pregnancy depression doubling the odds. Most cited medical reasons during pregnancy but shifted to recreational use postpartum.
Decade-long review of chronic pain drug trials found no breakthroughs, but identified CBD as one of only two drugs tested across fibromyalgia, CRPS, and chronic low back pain, with cannabinoid mechanisms among the most promising targets.
Mouse study found low-dose CBD combined with standard IBD drugs olsalazine or cyclosporine enhanced treatment beyond either alone without liver or kidney toxicity.
Review found the endocannabinoidome network shows promise for treating IBD complications beyond the gut, including joint, skin, liver, and eye manifestations.
Baboon study found alcohol dilates fetal brain arteries through CB1 cannabinoid receptors, with effects differing between male and female fetuses and across brain regions.
Evidence links prenatal cannabis to low birth weight, preterm birth, and lasting brain changes in children—with THC potency having risen from 5% to 30%.
Arkansas analysis found seven high-volume physicians certified over 1,000 patients each for medical marijuana with minimal evidence of prior patient contact, while low-volume certifiers showed care coordination.
Systematic review of 9 studies found cannabis affects the human microbiome across multiple body sites, with beneficial effects at moderate use and reduced diversity with heavy consumption.
Study of 96,482 youth found cannabis use moderated the bullying-suicidality link in LGBTQ+ teens, while opioid and hallucinogen use dramatically increased suicide attempt risk.
Review found oral CBD has only 6-19% bioavailability due to liver metabolism, while transdermal delivery offers improved absorption by bypassing the digestive system.
Survey of 1,382 women with chronic pelvic pain and fibromyalgia found 81% of current CBD users reported pain improvement, with correlated improvements in sleep, mood, and fatigue.
National survey found 74% of vape shops across 48 states sell intoxicating cannabis products, with 188 unique brands and substantial market competition.
Alzheimer's mouse study found endocannabinoid system disruption and immune activation in the retina before brain plaques formed, suggesting the eye as an early diagnostic window.
Review found phytocannabinoids like THCV and CBD may modulate kidney glucose transporters for diabetes management, with pilot data showing THCV lowers fasting glucose without psychoactive effects.
An analysis of emergency department data found rising visits for cannabinoid hyperemesis syndrome among adolescents, highlighting a growing clinical concern as youth cannabis use evolves.
CB1 activation in the prefrontal cortex impaired spatial memory formation in mice by reducing GABA release—a specific mechanism explaining THC's memory effects.
60-day study found negative consequences from mixing alcohol and cannabis paradoxically increased cannabis use at the next drinking event while reducing alcohol quantity.
Rat study found chronic CBD prevented Alzheimer's-like cognitive decline by activating CB1 receptors and reducing brain inflammation, amyloid-beta, and tau pathology.
Review found cannabinoids show anti-inflammatory therapeutic potential across six neurodegenerative and neuroinflammatory conditions by simultaneously targeting neural and immune pathways.
A survey of 258 chronic pain patients found positive expectations about cannabis, not pain severity, were the strongest predictor of use frequency and problematic use.
Lab experiments found a 3:1 CBD:THC combination killed ovarian cancer cells more effectively than either cannabinoid alone through apoptosis and autophagy.